Status:
COMPLETED
The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus
Lead Sponsor:
University Hospital Hradec Kralove
Conditions:
Hydrocephalus
Brain Damage
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Neurofilament Light Chain Protein (NfL) has been found by many studies as a sensitive biomarker of neuronal damage from several reasons, e.g. neurodegenerative diseases (Alzheimer's disease, Multiple ...
Eligibility Criteria
Inclusion
- In group A:
- Patients with diagnosed communicating hydrocephalus
- MMSE \> 10 points
- Absence of any structural laesion on MRI or CT
- Accepted Informed consent
- In group B:
- MMSE \> 10 points
- Absence of any structural laesion on MRI or CT
- Accepted Informed consent
- Elective spinal surgery without affecting dural sac and the spinal cord
- Surgery shorter than 120 minutes of lasting the general anesthesia
Exclusion
- Non-communicating hydrocephalus
- Structural laesion on MRI or CT (tumour, contusion, aneurysm)
- MMSE \< 10 points
- Life-expectancy shorter than 1 year
- Pre-existing other type of demetia (m. Alzheimer, vascular dementia)
- Surgery lasting more than 120 minutes
- Blood loss more than 500 ml
- Opening of dural sac (liquororhea)
- Adverse events during general anestesia: MAP\<60 mm Hg more than 5 minutes, arythmia with need for farmacological treatment
Key Trial Info
Start Date :
December 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 27 2025
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT05399602
Start Date
December 7 2023
End Date
September 27 2025
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Hradec Kralove
Hradec Králové, Czechia, 50005